Evonik Industries Bundle
What is the history of Evonik Industries?
Evonik Industries AG, a global leader in specialty chemicals, was established on September 12, 2007, following the restructuring of RAG AG. Its chemical heritage, however, extends much further back, primarily to Degussa GmbH, founded in 1873.
The company's formation aimed to build a new industrial base, supporting the liabilities of the declining German coal mining sector while expanding internationally. Today, Evonik is a major player in specialty chemicals, focusing on high-value products and solutions.
Evonik's journey began with Degussa, initially a precious metals refinery that grew into a significant chemical corporation. The company's strategic evolution has positioned it as a key provider across diverse sectors, offering innovative solutions like those analyzed in the Evonik Industries BCG Matrix.
What is the Evonik Industries Founding Story?
The formal establishment of Evonik Industries AG occurred on September 12, 2007, marking a significant restructuring of RAG AG. Evonik emerged from the 'white area' of RAG, consolidating its chemical, energy, and real estate subsidiaries. The company's chemical roots trace back to Degussa GmbH, acquired by RAG in 2006, which itself was founded in 1873.
The Genesis of Evonik Industries
Evonik Industries was born from a strategic decision to separate RAG AG's competitive international businesses from its core coal mining operations. This move aimed to create a new industrial foundation capable of financing the long-term liabilities associated with mining.
- The RAG Foundation, established July 10, 2007, became the primary owner of Evonik.
- Evonik's dividends and share sale revenues were designated to fund the closure of Western German coal mining.
- The name 'Evonik' was conceived by Manfred Gotta, blending the Latin 'Evo' (stem/germ) with 'evolvere' (to develop).
- This rebranding from RAG Beteiligungs-AG was a prelude to a planned initial public offering (IPO).
The initial plans for an IPO in the first half of 2008 were ultimately postponed. Consequently, the RAG Foundation sought strategic investors, leading to CVC Capital Partners acquiring a 25.01% stake in June 2008. This period highlights a key phase in the Competitors Landscape of Evonik Industries, showcasing its early corporate structure and strategic partnerships.
Evonik Industries SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Evonik Industries?
The foundations of Evonik Industries trace back to the rich histories of its predecessor companies, most notably Degussa, established in 1873. Degussa's early years were marked by significant international expansion and pioneering chemical innovations. This period laid the groundwork for the future specialty chemicals giant.
Early International Expansion of Degussa
Degussa, founded in 1873, quickly established a global presence. By the late 19th century, it had opened factories in the USA, including locations at Niagara Falls and Perth Amboy. This early international reach was a key aspect of its growth strategy.
Pioneering Chemical Innovations
The company was at the forefront of chemical advancements, achieving the synthesis of indigo in 1901. Furthermore, its development of perborates and percarbonates in the early 1900s directly led to the creation of modern detergents like Persil, first introduced in 1907.
Goldschmidt's Contributions to Specialty Chemicals
Another crucial predecessor, Chemische Fabrik Th. Goldschmidt, founded in 1847, made significant contributions. Relocating to Essen in 1890, it became known for its innovative tin recycling process and the thermite process for welding rail tracks. By the 1920s, Goldschmidt ventured into organic specialty chemicals, developing its own surfactants.
Consolidation and Formation of Evonik Industries
The late 1990s and early 2000s saw major consolidations in the German chemical sector. Mergers involving Hüls AG, Degussa AG, and SKW Trostberg AG led to the formation of the 'new' Degussa AG in 2001. RAG AG progressively increased its stake, fully acquiring Degussa by September 2006. In September 2007, Evonik Industries was established, integrating RAG's chemicals, energy, and real estate businesses. By 2009, Evonik had strategically repositioned itself solely as a specialty chemicals company, divesting its other segments to concentrate on its core chemical operations, a move that reflected the significant weight and profitability of its chemical divisions. This transformation is a key part of the Growth Strategy of Evonik Industries.
Evonik Industries PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Evonik Industries history?
The Evonik Industries history is a narrative of chemical innovation and strategic adaptation, tracing its roots back to pioneering companies. The company's evolution is marked by significant investments, key acquisitions, and ongoing efforts to streamline its operations and enhance efficiency in a competitive global market.
| Year | Milestone |
|---|---|
| 1901 | Degussa synthesized indigo, marking an early chemical innovation. |
| 1930s | Röhm & Haas developed PLEXIGLAS®, a significant material innovation. |
| 2010 | Acquired Tippecanoe Laboratories from Eli Lilly, expanding API manufacturing. |
| 2017 | Completed the acquisition of Air Products' specialty additives business for approximately US$3.8 billion. |
| 2023 | Acquired Oxypur in December, continuing its strategy of targeted acquisitions. |
| 2025 | Streamlining operations into two core segments: Custom Solutions and Advanced Technologies. |
Evonik has consistently driven innovation, exemplified by its early synthesis of indigo and the development of PLEXIGLAS®. More recently, the company has focused on high-value-added products and system solutions, with its specialty chemicals business contributing approximately 80% of sales in leading market positions.
DL-Methionine Plant in Singapore
The opening of a DL-methionine plant in Singapore represented a €500 million investment, which was the largest in the chemical sector for the company at that time, underscoring its commitment to expanding production capacity for key products.
Strategic Acquisitions
The acquisition of Air Products' specialty additives business for approximately US$3.8 billion in 2017 significantly strengthened its market presence in specialty additives. This was followed by 16 acquisitions across sectors like 3D Printing and Nanotechnology, including Oxypur in December 2023, demonstrating a continuous drive to enhance its portfolio.
Commitment to Research and Development
Evonik's R&D expenses in 2024 were €459 million, representing a 3.0% R&D ratio. The company actively protects its innovations, holding approximately 21,400 patents and filing 223 new patent applications in 2023, showcasing a strong focus on future growth through scientific advancement.
Evonik has navigated market downturns and competitive pressures through significant restructuring and efficiency programs. The company is currently implementing the 'Evonik Tailor Made' efficiency program, aiming to achieve €400 million in annual cost savings by 2026.
Group Restructuring
In June 2014, the Supervisory Board approved a restructuring to bundle its six chemical segments into three limited liability companies starting in 2015. This move was designed to simplify the corporate structure and improve operational focus.
Operational Streamlining
Effective April 1, 2025, Evonik is streamlining its operations into two core segments: Custom Solutions and Advanced Technologies. This initiative aims to accelerate decision-making and reduce bureaucracy by eliminating over 3,000 organizational units and reducing management levels.
Efficiency Programs
The 'Evonik Tailor Made' efficiency program targets €400 million in annual cost savings by 2026. This program is a critical component of the company's strategy to enhance profitability and competitiveness in the evolving chemical industry landscape. Understanding the Revenue Streams & Business Model of Evonik Industries provides context for these strategic adjustments.
Evonik Industries Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Evonik Industries?
The Evonik company background reveals a rich history of mergers and innovations, tracing its origins back to several key predecessor companies. This evolution has shaped its current strategic focus on sustainable growth and technological advancement, reflecting a deep commitment to its Mission, Vision & Core Values of Evonik Industries.
| Year | Key Event |
|---|---|
| 1847 | Chemische Fabrik Th. Goldschmidt, a predecessor, was founded in Berlin. |
| 1873 | Aktiengesellschaft Deutsche Gold- und Silber-Scheideanstalt vormals Roessler (Degussa), another key predecessor, was established in Frankfurt am Main. |
| 1901 | Degussa successfully synthesized indigo. |
| 1930s | Röhm & Haas, a company whose origins are traced by Evonik, developed PLEXIGLAS®. |
| 1968 | Ruhrkohle AG, the ultimate parent company of Evonik's origins, was founded. |
| 1999 | Hüls AG and Degussa AG merged to form Degussa-Hüls AG. |
| 2001 | Degussa-Hüls AG merged with SKW Trostberg AG to form the 'new' Degussa AG. |
| 2006 | RAG acquired Degussa AG. |
| 2007 | Evonik Industries AG was formally established from the restructuring of RAG AG. |
| 2010 | Evonik acquired the Tippecanoe Labs plant site from Eli Lilly. |
| 2013 | Evonik shares began trading on the Frankfurt Stock Exchange. |
| 2014 | The Supervisory Board resolved to restructure the Group, bundling chemical segments from 2015. |
| 2017 | Evonik completed the acquisition of Air Products' specialty additives business. |
| 2023 | Evonik's most recent acquisition was Oxypur. |
| 2024 | Evonik inaugurated the world's first industrial-scale plant for rhamnolipids in Slovakia. |
| 2025 | A new segment-based structure (Custom Solutions and Advanced Technologies) took effect. |
Innovation Growth Areas
Evonik aims to generate an additional €1.5 billion in sales by 2032 from three new innovation growth areas. These focus on bio-based solutions, energy transition, and circular economy principles.
Sustainability Targets
By 2030, Evonik targets 50% of its revenue from 'Next Generation Solutions', an increase from 45% in 2024. The company also plans a 25% reduction in Scope 1 and Scope 2 emissions by 2030.
Financial Outlook 2025
In Q1 2025, adjusted EBITDA rose 7% to €560 million, with free cash flow up 53% to €195 million. The company confirmed its 2025 adjusted EBITDA outlook of €2.0 billion to €2.3 billion.
Long-Term Financial Goals
Evonik aims to increase adjusted EBITDA by €1 billion by 2027 compared to 2023, targeting a ROCE of around 11%. Investments include €5 million at the Geesthacht site by 2029 for logistics expansion.
Evonik Industries Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Evonik Industries Company?
- What is Growth Strategy and Future Prospects of Evonik Industries Company?
- How Does Evonik Industries Company Work?
- What is Sales and Marketing Strategy of Evonik Industries Company?
- What are Mission Vision & Core Values of Evonik Industries Company?
- Who Owns Evonik Industries Company?
- What is Customer Demographics and Target Market of Evonik Industries Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.